Official Title of Study: A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS -986226 (anti -ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab in Patients with Advanced Solid Tumors NCT Number: NCT03251924 Document Date (Date in which document was last revised): May 31, 2019 Page: 1 Protocol Number: CA021002 IND Number: 133,788 EUDRACT Number: 2017-000238-73 Date: 26-May-2017 Revised Date: 31-May-2019 CLINICAL PROTOCOL CA021002 A Phase 1/2 Dose Escalation and Combinatio n Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Eff icacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab in Patients with Advanced Solid Tumors Revised Protocol 04 Study Director/Medical Monitor Telephone (office): Fax: 24-hr Emergency Telephone Number USA: International: Bristol-Myers Squibb Research and Development Route 206 & Province Line Road Lawrenceville, NJ 08543 Avenue de Finlande 4 B-1420 Braine-l’Alleud, Belgium This document is the confidential and proprietary information of Bristol-Myers Squibb Company and its global affiliates (BMS). By reviewing this document, you agree to keep it confidential and to use and disclose it so lely for the purpose of assessing whether your organization will participate in and/or th e performance of the proposed BMS sponsored study.